<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The intravenous administration of abciximab can be used as an adjuvant therapy to facilitate thrombolysis for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0596298" disease_type="Disease or Syndrome" abbrv="">cerebrovascular occlusion</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, to our knowledge, the intraaterial administration of abciximab has not been reported </plain></SENT>
<SENT sid="2" pm="."><plain>We recently treated three patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mp ids='MP_0005048'>thrombosis</z:mp> of the cerebral arteries by using an intraarterial infusion of urokinase and abciximab </plain></SENT>
<SENT sid="3" pm="."><plain>Even with small doses, we achieved rapid and complete recanalization without complications </plain></SENT>
<SENT sid="4" pm="."><plain>We believe that the intraarterial infusion of abciximab may be promising for effective and safe recanalization of <z:hpo ids='HP_0011009'>acute</z:hpo> thrombotic occlusion of cerebral arteries </plain></SENT>
</text></document>